Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Fermi America slumped 11.5% as it unveiled a $375 million convertible note offering and reported a Q1 with zero reven...
America’s debt has surged to WWII-era levels even as growth accelerates. Here’s what the numbers show and why investo...
A former SWIFT official punctured rumors that Ripple XRP could be integrated into SWIFT's payments network. At the sa...
Vodafone Group shares jumped about 13% after a dramatic stake reshuffle that makes Vega the largest shareholder. The ...
A pure bitcoin-miner fund surged, delivering gains far beyond a wide blockchain ETF as crypto markets rebounded. Here...
A $28 billion AI hardware IPO is trading at about 7x forward earnings, sparking a heated debate: is it a disrupted, d...
A large IRA move at 63 can trigger higher Medicare premiums for years, thanks to a two year income lookback. Near ret...
Anthropic and Airbnb are placing big bets on New York City, expanding footprints and hiring aggressively while critic...
Ultra-wealth households are paying premium to private staff amid a tightening labor market, with some packages includ...
Ciena’s shares jumped sharply in the first half of 2026. This article dives into the AI-driven demand for optical net...
A new player in the chip foundry race is signaling aggressive pricing. If a potential rival wants undercut, investors...